Climb Bio (CLYM) Stock Price, News & Analysis

Climb Bio logo
$9.17 -0.11 (-1.19%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$9.18 +0.02 (+0.16%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Climb Bio Stock (NASDAQ:CLYM)

Advanced

Key Stats

Today's Range
$8.90
▼
$9.40
50-Day Range
$8.81
▼
$14.56
52-Week Range
$1.63
▼
$18.33
Volume
770,171 shs
Average Volume
1.32 million shs
Market Capitalization
$538.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.14
Consensus Rating
Buy

Company Overview

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production.

Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy.

Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity. The program is being explored for potential use in IgA nephropathy and other immune-related conditions.

AI Generated. May Contain Errors.

Climb Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

CLYM MarketRank™: 
2.40085967831 of 5 stars

Climb Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 351st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Climb Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Climb Bio has a consensus price target of $28.14, representing about 206.9% upside from its current price of $9.17.

  • Amount of Analyst Coverage

    Climb Bio has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Climb Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Climb Bio are expected to decrease in the coming year, from ($0.75) to ($0.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Climb Bio is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Climb Bio is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Climb Bio has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.88% of the float of Climb Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Climb Bio has a short interest ratio ("days to cover") of 7.76.
  • Change versus previous month

    Short interest in Climb Bio has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Climb Bio does not currently pay a dividend.

  • Dividend Growth

    Climb Bio does not have a long track record of dividend growth.

  • News Sentiment

    Climb Bio has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Climb Bio this week, compared to 4 articles on an average week.
  • Search Interest

    Only 7 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Climb Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,367,000.00 in company stock.

  • Percentage Held by Insiders

    2.60% of the stock of Climb Bio is held by insiders.

  • Percentage Held by Institutions

    69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Climb Bio's insider trading history.
Receive CLYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLYM Stock News Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Climb Bio Stock Earnings Estimates Raised by HC Wainwright
See More Headlines

CLYM Stock Analysis - Frequently Asked Questions

Climb Bio's stock was trading at $4.00 at the beginning of the year. Since then, CLYM stock has increased by 129.3% and is now trading at $9.17.

Climb Bio, Inc. (NASDAQ:CLYM) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.02.

Climb Bio (CLYM) raised $80 million in an IPO on Thursday, August 5th 2021. The company issued 6,400,000 shares at $12.50 per share.

Climb Bio's top institutional shareholders include RA Capital Management L.P. (17.25%), State Street Corp (3.15%), Great Point Partners LLC (1.36%) and Integral Health Asset Management LLC (1.19%). Insiders that own company stock include Ra Capital Management, LP, Stephen Basil Thomas and Emily Pimblett.
View institutional ownership trends
.

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Climb Bio investors own include NVIDIA (NVDA), Aclaris Therapeutics (ACRS), AeroVironment (AVAV), Cabaletta Bio (CABA), Definium Therapeutics (DFTX), TuHURA Biosciences (HURA) and Immunic (IMUX).

Company Calendar

Last Earnings
11/05/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLYM
Previous Symbol
NASDAQ:CLYM
CIK
1768446
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

High Price Target
$40.00
Low Price Target
$18.00
Potential Upside/Downside
+206.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-30.57%
Return on Assets
-29.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.58
Quick Ratio
26.58

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.88 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
58,740,000
Free Float
57,211,000
Market Cap
$538.65 million
Optionable
Optionable
Beta
0.01
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:CLYM) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners